Antibodies reacting with JCPyV_VP2 _167-15mer as a novel serological marker for JC polyomavirus infection

Virology Journal

Lieven J Stuyver²  Luc Tritsmans¹  Tom Van Loy²  Ole Lagatie² 

[1] Janssen Research and Development, Turnhoutseweg 30, 2340 Beerse, Belgium;Janssen Diagnostics, Turnhoutseweg 30, 2340 Beerse, Belgium

关键词: Progressive Multifocal Leukoencephalopathy;    VP2;    Peptide serology;    Biomarker;    JC Polyomavirus;   

Others  :  1148248
DOI  :  10.1186/1743-422X-11-174

 received in 2014-06-26, accepted in 2014-09-27,  发布年份 2014

【 摘 要 】

Background

JC polyomavirus (JCPyV) is a widespread human polyomavirus that usually resides latently in its host, but can be reactivated under immune-compromised conditions potentially causing Progressive Multifocal Leukoencephalopathy (PML). Detection of antibodies against the major capsid protein VP1 currently is the main marker for assessment of infection with JCPyV.

Methods

Based on a peptide microarray, peptide JCPyV_VP2_167-15mer was selected and a peptide ELISA was developed for detection of antibodies directed against this peptide. Epitope mapping and computational modelling was performed to further characterize this peptide. In a cohort of 204 healthy subjects it was investigated whether antibodies against JCPyV_VP2_167-15mer were correlated with VP1 serology or urinary viral load.

Results

Epitope mapping of peptide JCPyV_VP2_167-15mer showed that the minimal epitope consisted of L₁₇₃PALTSQEI₁₈₁ with amino acids P₁₇₄, L₁₇₆ and E₁₈₀ being essential for antibody recognition. Computational analysis was used to predict that this epitope is located at an exposed domain of the VP2 capsid protein, readily accessible for immune recognition upon infection. No correlation could be observed with JCPyV VP1 antibody levels, or urinary viral load.

Conclusion

This work indicates that specific antibodies against JCPyV_VP2_167-15mer might be considered as a novel serological marker for infection with JCPyV.

【 授权许可】

   
2014 Lagatie et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Frisque RJ, Bream GL, Cannella MT: Human polyomavirus JC virus genome. J Virol 1984, 51(2):458-469.
• [2]Padgett BL, Rogers CM, Walker DL: JC virus, a human polyomavirus associated with progressive multifocal leukoencephalopathy: additional biological characteristics and antigenic relationships. Infect Immun 1977, 15(2):656-662.
• [3]Berger JR, Major EO: Progressive multifocal leukoencephalopathy. Semin Neurol 1999, 19(2):193-200.
• [4]Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH: Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1971, 1(7712):1257-1260.
• [5]Dubois V, Dutronc H, Lafon ME, Poinsot V, Pellegrin JL, Ragnaud JM, Ferrer AM, Fleury HJ: Latency and reactivation of JC virus in peripheral blood of human immunodeficiency virus type 1-infected patients. J Clin Microbiol 1997, 35(9):2288-2292.
• [6]Andreoletti L, Dubois V, Lescieux A, Dewilde A, Bocket L, Fleury HJ, Wattre P: Human polyomavirus JC latency and reactivation status in blood of HIV-1-positive immunocompromised patients with and without progressive multifocal leukoencephalopathy. Aids 1999, 13(12):1469-1475.
• [7]Weissert R: Progressive multifocal leukoencephalopathy. J Neuroimmunol 2011, 231(1–2):73-77.
• [8]Gasparovic ML, Gee GV, Atwood WJ: JC virus minor capsid proteins Vp2 and Vp3 are essential for virus propagation. J Virol 2006, 80(21):10858-10861.
• [9]Shishido-Hara Y, Ichinose S, Higuchi K, Hara Y, Yasui K: Major and minor capsid proteins of human polyomavirus JC cooperatively accumulate to nuclear domain 10 for assembly into virions. J Virol 2004, 78(18):9890-9903.
• [10]Giorda KM, Raghava S, Zhang MW, Hebert DN: The viroporin activity of the minor structural proteins VP2 and VP3 is required for SV40 propagation. J Biol Chem 2013, 288(4):2510-2520.
• [11]Knowles WA, Pipkin P, Andrews N, Vyse A, Minor P, Brown DW, Miller E: Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 2003, 71(1):115-123.
• [12]Lee P, Plavina T, Castro A, Berman M, Jaiswal D, Rivas S, Schlain B, Subramanyam M: A second-generation ELISA (STRATIFY JCV DxSelect) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol 2013, 57(2):141-146.
• [13]Major EO: Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010, 61:35-47.
• [14]Van Loy T, Thys K, Tritsmans L, Stuyver LJ: Quasispecies analysis of JC virus DNA present in urine of healthy subjects. PLoS One 2013, 8(8):e70950.
• [15]Padgett BL, Walker DL: Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy. J Infect Dis 1973, 127(4):467-470.
• [16]Taguchi F, Kajioka J, Miyamura T: Prevalence rate and age of acquisition of antibodies against JC virus and BK virus in human sera. Microbiol Immunol 1982, 26(11):1057-1064.
• [17]Walker DL, Padgett BL: The epidemiology of human polyomaviruses. Prog Clin Biol Res 1983, 105:99-106.
• [18]Randhawa P, Viscidi R, Carter JJ, Galloway DA, Culp TD, Huang C, Ramaswami B, Christensen ND: Identification of species-specific and cross-reactive epitopes in human polyomavirus capsids using monoclonal antibodies. J Gen Virol 2009, 90(Pt 3):634-639.
• [19]Viscidi RP, Clayman B: Serological cross reactivity between polyomavirus capsids. Adv Exp Med Biol 2006, 577:73-84.
• [20]Dominguez-Mozo MI, Garcia-Montojo M, De Las HV, Garcia-Martinez A, Arias-Leal AM, Casanova I, Arroyo R, Alvarez-Lafuente R: Anti-JCV antibodies detection and JCV DNA levels in PBMC, serum and urine in a cohort of Spanish Multiple Sclerosis patients treated with natalizumab. J Neuroimmune Pharmacol 2013, 8(5):1277-1286.
• [21]Plavina T, Berman M, Njenga M, Crossman M, Lerner M, Gorelik L, Simon K, Schlain B, Subramanyam M: Multi-site analytical validation of an assay to detect anti-JCV antibodies in human serum and plasma. J Clin Virol 2012, 53(1):65-71.
• [22]Warnke C, Pawlita M, Dehmel T, Posevitz-Fejfar A, Hartung HP, Wiendl H, Kieseier BC, Adams O: An assay to quantify species-specific anti-JC virus antibody levels in MS patients. Mult Scler 2013, 19(9):1137-1144.
• [23]Kean JM, Rao S, Wang M, Garcea RL: Seroepidemiology of human polyomaviruses. PLoS Pathog 2009, 5(3):e1000363.
• [24]Moens U, Van Ghelue M, Song X, Ehlers B: Serological cross-reactivity between human polyomaviruses. Rev Med Virol 2013, 23(4):250-264.
• [25]Food-and-Drug-Administration: Anti- John Cunningham Virus (JCV) antibodies measured by Enzyme Linked Immunosorbent Assay (ELISA); 510(k) Number: K112394. 2012. [http://www.accessdata.fda.gov/cdrh_docs/reviews/K112394.pdf webcite] webcite
• [26]Zhang NN, Zhao LQ, Qian Y, Zhu RN, Deng J, Wang F, Sun Y, Liu LY: Common WU polyomavirus infection in a Beijing population indicated by surveillance for serum IgG antibody against capsid protein VP2. World J Pediatr 2013, 9(1):48-52.
• [27]Corallini A, Mazzoni E, Taronna A, Manfrini M, Carandina G, Guerra G, Guaschino R, Vaniglia F, Magnani C, Casali F, Dolcetti R, Palmonari C, Rezza G, Martini F, Barbanti-Brodano G, Tognon MG: Specific antibodies reacting with simian virus 40 capsid protein mimotopes in serum samples from healthy blood donors. Hum Immunol 2012, 73(5):502-510.
• [28]Mueller K, Schachtner T, Sattler A, Meier S, Friedrich P, Trydzenskaya H, Hinrichs C, Trappe R, Thiel A, Reinke P, Babel N: BK-VP3 as a new target of cellular immunity in BK virus infection. Transplantation 2011, 91(1):100-107.
• [29]Stuyver LJ, Verbeke T, Van Loy T, Van Gulck E, Tritsmans L: An antibody response to human polyomavirus 15-mer peptides is highly abundant in healthy human subjects. Virol J 2013, 10:192. BioMed Central Full Text
• [30]Cunningham BC, Wells JA: Comparison of a structural and a functional epitope. J Mol Biol 1993, 234(3):554-563.
• [31]Cunningham BC, Wells JA: High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. Science 1989, 244(4908):1081-1085.
• [32]Zheng HY, Sugimoto C, Hasegawa M, Kobayashi N, Kanayama A, Rodas A, Mejia M, Nakamichi J, Guo J, Kitamura T, Yogo Y: Phylogenetic relationships among JC virus strains in Japanese/Koreans and Native Americans speaking Amerind or Na-Dene. J Mol Evol 2003, 56(1):18-27.
• [33]Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ: Basic local alignment search tool. J Mol Biol 1990, 215(3):403-410.
• [34]Egli A, Infanti L, Dumoulin A, Buser A, Samaridis J, Stebler C, Gosert R, Hirsch HH: Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 2009, 199(6):837-846.
• [35]Antonsson A, Green AC, Mallitt KA, O’Rourke PK, Pawlita M, Waterboer T, Neale RE: Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians. J Gen Virol 2010, 91(Pt 7):1849-1853.
• [36]Stolt A, Sasnauskas K, Koskela P, Lehtinen M, Dillner J: Seroepidemiology of the human polyomaviruses. J Gen Virol 2003, 84(Pt 6):1499-1504.
• [37]Frohman EM, Monaco MC, Remington G, Ryschkewitsch C, Jensen PN, Johnson K, Perkins M, Liebner J, Greenberg B, Monson N, Frohman TC, Douek D, Major EO: JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab. JAMA Neurol 2014, 71(5):596-602.
• [38]Major EO, Frohman E, Douek D: JC viremia in natalizumab-treated patients with multiple sclerosis. N Engl J Med 2013, 368(23):2240-2241.
• [39]Major EO, Frohman E, Douek D: More on JC viremia in natalizumab-treated patients with multiple sclerosis. N Engl J Med 2013, 369(13):1280.
• [40]Berger JR, Houff SA, Gurwell J, Vega N, Miller CS, Danaher RJ: JC virus antibody status underestimates infection rates. Ann Neurol 2013, 74(1):84-90.
• [41]Diotti RA, Mancini N, Clementi N, Sautto G, Moreno GJ, Criscuolo E, Cappelletti F, Man P, Forest E, Remy L, Giannecchini S, Clementi M, Burioni R: Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: epitope definition and implications in risk stratification of patients under natalizumab therapy. Antivir Res 2014, 108:94-103.
• [42]Streckert HJ, Sommerfeld HJ, Morgenroth K, Werchau H: Recognition of SV40-VP2 in the infected cell by antipeptide antibodies. Arch Virol 1992, 123(3–4):399-407.
• [43]Chen XS, Stehle T, Harrison SC: Interaction of polyomavirus internal protein VP2 with the major capsid protein VP1 and implications for participation of VP2 in viral entry. EMBO J 1998, 17(12):3233-3240.
• [44]Burkert O, Kressner S, Sinn L, Giese S, Simon C, Lilie H: Biophysical characterization of polyomavirus minor capsid proteins. Biol Chem 2014, 395(7-8):871-880.
• [45]Lagatie O, Van Loy T, Tritsmans L, Stuyver LJ: Circulating human microRNAs are not linked to JC polyomavirus serology or urinary viral load in healthy subjects. Virol J 2014, 11(1):41. BioMed Central Full Text
• [46]Alland C, Moreews F, Boens D, Carpentier M, Chiusa S, Lonquety M, Renault N, Wong Y, Cantalloube H, Chomilier J, Hochez J, Pothier J, Villoutreix BO, Zagury JF, Tuffery P: RPBS: a web resource for structural bioinformatics. Nucleic Acids Res 2005, 33(Web Server issue):W44-W49.
• [47]Neron B, Menager H, Maufrais C, Joly N, Maupetit J, Letort S, Carrere S, Tuffery P, Letondal C: Mobyle: a new full web bioinformatics framework. Bioinformatics 2009, 25(22):3005-3011.